PDL Ditches Cardene, Other Heart Failure Meds As Part Of Restructuring Plan
This article was originally published in The Pink Sheet Daily
Executive Summary
In a surprise move, former ESP Pharma executive snaps assets back up from PDL at what some consider a bargain-basement price.
You may also be interested in...
Scant Worry Over PDL Patent Challenges
Firm forges ahead with plans to split off biotech operations.
Scant Worry Over PDL Patent Challenges
Firm forges ahead with plans to split off biotech operations.
PDL Can’t Find Buyer, Plans More Cutbacks
Fourth-quarter numbers disappoint, but savings could brighten picture.